IMR Press / CEOG / Volume 38 / Issue 4 / pii/1630543038085-525770491

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research
Distribution of etiological factors of hypergonadotropic amenorrhea
Show Less
1 Department of Obstetrics and Gynecology,University Medical Centre Ljubljana, Ljubljana
2 Gynecology Outpatient Clinic Dr. Franic, Rogaska Slatina (Slovenia)
Clin. Exp. Obstet. Gynecol. 2011, 38(4), 369–372;
Published: 10 December 2011

Objective: To describe the etiology of hypergonadotropic amenorrhea (HA) and outline the subgroup of infertile women that might achieve pregnancy with their own egs despite premature ovarian failure. Methods: In this retrospective study we enrolled 70 women aged 32.5 ± 5.71 years. After a detailed history of the disease, measurements of follicle-stimulating hormone, estradiol, prolactin and thyroid-stimulating hormone levels, determination of the karyotype and fragile X premutation syndrome, and a quick ACTH test, estro-gen-progestin replacement therapy was introduced. Results: In 17 of the 70 women. HA was due to chromosomal abnormalities, in 16to extensive gynecologic surgery, in ten to oral contraceptive use, in four to chemo- and radiotherapy in 23 HA was idiopathic. After estrogen-progestin replacement therapy, three women with idiopathic HA conceived and delivered healthy babies. Conclusion: Estro-gen-progestin replacement therapy in pharmacological doses might be beneficial to women with idiopathic HA, having normal pro-lactin levels, adrenal and thyroid function, and a normal karyotype.
Estrogen-progestin treatment
Hypergonadotropic amenorrhea
Back to top